Literature DB >> 10341268

Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice.

C J Serpe1, A P Kohm, C B Huppenbauer, V M Sanders, K J Jones.   

Abstract

The immune system functions to protect an organism against microbial infections and may be involved in the reparative response to nerve injury. The goal of this study was to determine whether the immune system plays a role in regulating motoneuron survival after a peripheral nerve injury. After a right facial nerve axotomy, facial motoneuron (FMN) survival in C.B-17 (+/+) wild-type mice was found to be 87 +/- 3.0% of the unaxotomized left side control. In contrast, facial nerve axotomy in C.B-17 (-/-) severe combined immunodeficient (scid) mice, lacking functional T and B lymphocytes, resulted in an average FMN survival of 55 +/- 3.5% relative to the unaxotomized left side control. This represented an approximately 40% decrease in FMN survival compared with wild-type controls. The reconstitution of scid mice with wild-type splenocytes containing T and B lymphocytes restored FMN survival in these mice to the level of the wild-type controls. These results suggest that immune cells associated with acquired immunity play a role in regulating motoneuron survival after a peripheral nerve injury.

Entities:  

Mesh:

Year:  1999        PMID: 10341268      PMCID: PMC6782611     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  68 in total

1.  Protective autoimmunity is a physiological response to CNS trauma.

Authors:  E Yoles; E Hauben; O Palgi; E Agranov; A Gothilf; A Cohen; V Kuchroo; I R Cohen; H Weiner; M Schwartz
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

2.  Age and facial nerve axotomy-induced T cell trafficking: relation to microglial and motor neuron status.

Authors:  Daniel J Dauer; Zhi Huang; Grace K Ha; Jeremy Kim; David Khosrowzadeh; John M Petitto
Journal:  Brain Behav Immun       Date:  2010-08-19       Impact factor: 7.217

3.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

Review 4.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

Review 5.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 6.  Microglia and the control of autoreactive T cell responses.

Authors:  Benoit Melchior; Shweta S Puntambekar; Monica J Carson
Journal:  Neurochem Int       Date:  2006-06-08       Impact factor: 3.921

7.  Prior facial motor neuron injury elicits endogenous T cell memory: relation to neuroregeneration.

Authors:  Grace K Ha; Zhi Huang; John M Petitto
Journal:  J Neuroimmunol       Date:  2007-01-17       Impact factor: 3.478

8.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

9.  Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide.

Authors:  B D Armstrong; C Abad; S Chhith; G Cheung-Lau; O E Hajji; H Nobuta; J A Waschek
Journal:  Neuroscience       Date:  2007-10-30       Impact factor: 3.590

10.  Immunodeficiency impairs re-injury induced reversal of neuronal atrophy: relation to T cell subsets and microglia.

Authors:  Grace K Ha; Zhi Huang; Ravi Parikh; Marlon Pastrana; John M Petitto
Journal:  Exp Neurol       Date:  2007-08-01       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.